NCT01898715View on ClinicalTrials.gov

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 13, 2013

Primary Completion Date

November 2, 2016

Study Completion Date

October 17, 2017

Conditions
Adrenocortical CarcinomaAdrenal CancerACC
Interventions
DRUG

ATR-101

Trial Locations (5)

20892

National Institutes of Health/National Cancer Institute, Bethesda

33612

Moffitt Cancer Center, Tampa

48103

University of Michigan Cancer Center, Ann Arbor

77030

MDAnderson Cancer Center, Houston

Unknown

Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg

Sponsors
All Listed Sponsors
lead

Millendo Therapeutics, Inc.

INDUSTRY

NCT01898715 - Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | Biotech Hunter | Biotech Hunter